XIFAXAN

LOE Approaching

rifaximin

NDAORALTABLETPriority Review
Approved
Mar 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT07285785Phase 4Not Yet Recruiting

Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea

Started Dec 2025
NCT06718686Phase 1/2Recruiting

Rifaximin SSD in Dementia Trial

Started Dec 2024
NCT06312683Phase 4Recruiting

Rifaximin for the Secondary Prevention of Recurrent Pouchitis

Started Jul 2024
NCT05297448Phase 3Active Not Recruiting

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Started Aug 2022
NCT05453916Phase 1/2Withdrawn

Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

Started Jul 2022